

SEP 15 2003

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

P-073608A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	08/455,975
Filing Date	May 31, 1995
First Named Inventor	Jeffrey S. RUBIN et al.
Group Art Unit	1647
Examiner Name	C. Saoud
Attorney Docket Number	38163-0010

RECEIVED
U.S. PATENT & TRADEMARK OFFICE
SEP 1 2003
TECHNICAL DIVISION
100-0000000000000000

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ	D03	RALPH J. PANOS, "Keratinocyte Growth Factor and Hepatocyte Growth Factor/Scatter Factor Are Heparin-binding Growth Factors for Alveolar Type II Cells in Fibroblast-conditioned Medium", The Journal of Clinical Investigation, Inc., August 1993, pp. 969-977, Vol. 92	
	D04	THOMAS R. ULLICH et al., "Keratinocyte Growth Factor Is a Growth Factor for Type II Pneumocytes In Vivo", J. Clin. Invest., March 1994, pp. 1298-1306, Vol. 93	
	D05	Decision of Technical Board of Appeal 3.4.1, dated January 21, 1992, T 689/90-3.4.1; Applicant: Raychem Corporation; Headword: Event detector/RAYCHEM; Article: 78(1)(b), 123(2) EPC; Keyword: "Amendments based on cross-reference document identified in description"	
	D06	Decision of Technical Board of Appeal 3.3.4 dated April 8, 1997, T 207/94-3.3.4; Patent proprietor/Respondent: Biogen, Inc.; Opponent/Appellant: Schering AG; Headword: Human beta-interferon/BIOGEN; Article 87, 88, 54, 56 EPC; Keyword: "Priority-(yes)"-Novelty-(yes)"-Inventive step-(no)"	
	D07	Opposition Statement in Support of Opposition by Chiron Corporation to European Patent No. 0555205 in the Names of RUBIN et al., dated August 20, 2001, Deriving from European Patent Appl. No. 9093253.4 : Title: DNA Encoding A Growth Factor Specific for Epithelial Cells; date of Publication of Grant: 29.11.2000	
	D08	Proprietor: Jeffrey S. RUBIN et al., Opponent: Chiron Corporation; Opposition to EP 0 555 205 B1; Application No. 90 903 253.4-2404; dated August 22, 2002; Ref. No. EP 7386-03196/tc; Response to Opposition Brief dated August 20, 2001 and the belatedly filed supplementary statement of December 18, 2001	
	D09	Applicant: Jeffrey S. RUBIN et al., dated September 5, 2001, Ref.: EP 7386, Appl. No./Patent No.: 90903253.4-2405/0555205; Communication of a Notice of Opposition; EPO Form 2316 04.94	
	D10	Opposition by Chiron Corporation to EP-B 0555205 Deriving from European Patent Appl. No. 9093253.4-2110 RUBIN et al.; dated December 18, 2001, Declaration By Dr. Judith Abraham	
	D11	Applicant: Jeffrey S. RUBIN et al., dated October 2, 2002, Ref.: EP 7386, Appl. No./Patent No.: 90903253.4-2405/0555205; Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC; EPO Form 2310.1PH 11.00	
CJ	D12	Applicant: Jeffrey S. RUBIN et al., dated January 29, 2003, Ref.: EP 7386, Appl. No./Patent No.: 90903253.4-2405/0555205; Decision to Discontinue the Opposition Proceeding; EPO Form 2352 02.99	

Examiner
Signature

C. Saoud

Date
Considered

12/12/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

